.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,789,381

« Back to Dashboard

Details for Patent: 5,789,381

Title: Pulmonary surfactant proteins and related polypeptides
Abstract:The present invention discloses useful peptides and synthetic pulmonary surfactants, as well as methods of making and using same. In one preferred embodiment, a synthetic pulmonary surfactant comprises one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions. In other embodiments, a surfactant peptide has an amino acid residue sequence selected from the group consisting of KLLLLKLLLLKLLLLKLLLLK, KLLLLLLLLKLLLLLLLLKLL, and KKLLLLLLLKKLLLLLLLKKL.
Inventor(s): Cochrane; Charles G. (La Jolla, CA), Revak; Susan D. (San Diego, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Filing Date:Apr 11, 1995
Application Number:08/419,824
Claims:1. A pulmonary surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula KLLLLKLLLLKLLLLKLLLLK (SEQ. ID NO: 1), said polypeptide, thereby forming a pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone, said phospholipid being present in the range of about 50-100 weight percent, in a polypeptide:phospholipid weight ratio in the range of about 1:7 to about 1:1,000.

2. The pulmonary surfactant of claim 1, wherein said phospholipid is selected from the group consisting of:

1,2-dipalmitoyl-sn-glycero-3-phosphocholine (dipalmitoylphosphatidylcholine, DPPC);

phosphatidyl glycerol (PG); and

an admixture of DPPC and PG in a weight ratio of about 3:1.

3. The pulmonary surfactant of claim 1, further comprising palmitic acid, wherein said phospholipid comprises about 50-90 weight percent and said palmitic acid comprises the remaining 10-50 weight percent of said surfactant.

4. A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a pulmonary surfactant, said surfactant comprising one or more pharmaceutically acceptable phospholipids admixed with a polypeptide having an amino acid residue sequence represented by the formula KLLLLKLLLLKLLLLKLLLLK (SEQ. ID NO: 1) , said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone, said phospholipid being present in the range of about 50-100 weight percent, in a polypeptide:phospholipid weight ratio in the range of about 1:7 to about 1:1,000, or in an amount such that it may be administered in a range of about 50 mg/kg to about 500 mg/kg per dose.

5. The method of claim 4, wherein said phospholipid is selected from the group consisting of:

1,2-dipalmitoyl-sn-glycero-3-phosphocholine (dipalmitoylphosphatidylcholine, DPPC);

phosphatidyl glycerol (PG); and

an admixture of DPPC and PG in a weight ratio of about 3:1.

6. The method of claim 4, wherein said surfactant further comprises palmitic acid, and wherein said phospholipid comprises about 50-90 weight percent and said palmitic acid comprises the remaining 10-50 weight percent of the lipid portion of said surfactant.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc